Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors: A Multicenter, Single-arm, Phase II Clinical Study

NCT07841873 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT07841873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07841873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors: A Multicenter, Single-arm, Phase II Clinical Study
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2030
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer